An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro) and Calcium Acetate (Phoslyra) in Paediatric and Adolescent CKD Patients With Hyperphosphataemia
Phase of Trial: Phase III
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Sucroferric oxyhydroxide (Primary) ; Sucroferric oxyhydroxide (Primary) ; Calcium acetate
- Indications Hyperphosphataemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Vifor Fresenius Medical Care Renal Pharma
- 27 Sep 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Aug 2019.
- 23 Jun 2016 Status changed from not yet recruiting to recruiting.
- 25 Feb 2016 New trial record